These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11856905)

  • 1. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease.
    Mathur S; Devaraj S; Jialal I
    Curr Opin Nephrol Hypertens; 2002 Mar; 11(2):141-7. PubMed ID: 11856905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid metabolism abnormalities and atherosclerosis in patients on maintenance hemodialysis].
    Musiał J; Undas A; Sysło K
    Przegl Lek; 1994; 51(6):264-7. PubMed ID: 7938663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia and renal disease: pathogenesis and clinical consequences.
    Wanner C; Quaschning T
    Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):195-201. PubMed ID: 11224694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress in chronic renal failure.
    Hasselwander O; Young IS
    Free Radic Res; 1998 Jul; 29(1):1-11. PubMed ID: 9733016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of dyslipidemia in chronic kidney disease.
    Stefanovic V; Milojkovic M
    Int J Artif Organs; 2004 Oct; 27(10):821-7. PubMed ID: 15560675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation of low-density lipoprotein and atherosclerosis in chronic renal failure.
    Hasselwander O; Young IS
    Med Hypotheses; 1997 Nov; 49(5):389-95. PubMed ID: 9421803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremia-specific alterations in lipid metabolism.
    Wanner C; Krane V
    Blood Purif; 2002; 20(5):451-3. PubMed ID: 12207090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy.
    Islam KN; O'Byrne D; Devaraj S; Palmer B; Grundy SM; Jialal I
    Atherosclerosis; 2000 May; 150(1):217-24. PubMed ID: 10781654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of dyslipidemia in end-stage renal disease.
    Prichard SS
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S315-20. PubMed ID: 12939388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein heterogeneity in end-stage renal disease.
    Joven J; Vilella E; Ahmad S; Cheung MC; Brunzell JD
    Kidney Int; 1993 Feb; 43(2):410-8. PubMed ID: 8441237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atherosclerosis and arteriosclerosis of the small vessels in chronic renal insufficiency and after transplantation: lipid factors].
    Boizel R
    Nephrologie; 2000; 21(7):329-32. PubMed ID: 11200602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in chronic renal failure as a cardiovascular risk factor.
    Siems W; Quast S; Carluccio F; Wiswedel I; Hirsch D; Augustin W; Hampi H; Riehle M; Sommerburg O
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S12-9. PubMed ID: 12227720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL metabolism and activity in chronic kidney disease.
    Vaziri ND; Navab M; Fogelman AM
    Nat Rev Nephrol; 2010 May; 6(5):287-96. PubMed ID: 20308998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients.
    Wanner C; Zimmermann J; Quaschning T; Galle J
    Kidney Int Suppl; 1997 Nov; 62():S53-5. PubMed ID: 9350681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.